For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...

Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...

Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...

Since their policy announcement in 2019, becoming smokefree is a national priority for central government who set out their ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

A National Institute for Health and Care Research (NIHR) evidence collection brings together research on whether stratified care can help primary care teams manage long-term conditions. Stratified ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.

Researchers mapped the biological influences on 4,775 plasma proteins, revealing the interplay of modifiable and ...